From a mechanistic point of view, metformin can reduce histone acetylation at the CCR8 promoter and inhibit CCR8 expression on tumor-infiltrating Treg cells by upregulating AMPK-activated Sirtuin 2 (SIRT2), thus enhancing the effectiveness of anti-PD-1 immunotherapy (73). Here, CCR8 is linked to neoplasm.